IgG subclasses of disease-specific antibodies and complement activation in-vitro in seronegative myasthenia gravis and neuromyelitis optica

IgG subclasses of disease-specific antibodies and complement activation in-vitro in seronegative myasthenia gravis and neuromyelitis optica

Detalles Bibliográficos
Main Authors:	Jacob, S, Leite, M, Waters, P, Viegas, S, Cossins, J, Beeson, D, Morgan, B, Vincent, A
Formato:	Journal article
Publicado:	2008

Títulos similares

IgG subclasses of disease-specific antibodies and complement activation in vitro in myasthenia gravis and neuromyelitis optica
por: Jacob, S, et al.
Publicado: (2007)

IgG1 antibodies to acetylcholine receptors in 'seronegative' myasthenia gravis.
por: Leite, M, et al.
Publicado: (2008)

Antibodies to AChRs in seronegative myasthenia gravis
por: Leite, M, et al.
Publicado: (2006)

Myasthenia Gravis and Neuromyelitis Optica Association
por: J Gordon Millichap
Publicado: (2012-06-01)

Effect of IgG from seronegative and seropositive neuromyelitis optica patients on mouse brain
por: Saadoun, S, et al.
Publicado: (2013)

Myasthenia gravis seronegative for acetylcholine receptor antibodies.
por: Vincent, A, et al.
Publicado: (2008)

Inhibition of acetylcholine receptor function by seronegative myasthenia gravis non-IgG factor correlates with desensitisation.
por: Spreadbury, I, et al.
Publicado: (2005)

Antibodies to clustered acetylcholine receptor and thymic changes in seronegative myasthenia gravis
por: Leite, M, et al.
Publicado: (2007)

Neuromyelitis optica and longitudinally extensive transverse myelitis following thymectomy for myasthenia gravis
por: Jarius, S, et al.
Publicado: (2007)

Neuromyelitis optica IgG causes placental inflammation and fetal death.
por: Saadoun, S, et al.
Publicado: (2013)

Seronegative myasthenia gravis.
por: Vincent, A, et al.
Publicado: (2004)

NMO-IgG/Aqp4-Ab belongs to the IgG1 subclass and activates complement in vitro
por: Jarius, S, et al.
Publicado: (2007)

NMO-IgG in the diagnosis of neuromyelitis optica.
por: Jarius, S, et al.
Publicado: (2007)

SERONEGATIVE MYASTHENIA GRAVIS-CLINICAL/SEROLOGICAL ASPECTS
por: Huda, S, et al.
Publicado: (2014)

MuSK myasthenia gravis IgG4 disrupts the interaction of LRP4 with MuSK but both IgG4 and IgG1-3 can disperse preformed agrin-independent AChR clusters
por: Koneczny, I, et al.
Publicado: (2013)

MuSK myasthenia gravis IgG4 disrupts the interaction of LRP4 with MuSK but both IgG4 and IgG1-3 can disperse preformed agrin-independent AChR clusters.
por: Koneczny, I, et al.
Publicado: (2013)

Neuromyelitis optica IgG causes placental inflammation and fetal death in mice
por: Saadoun, S, et al.
Publicado: (2013)

Myasthenia gravis and neuromyelitis optica spectrum disorder: a multicenter study of 16 patients.
por: Leite, M, et al.
Publicado: (2012)

IgG from "seronegative" myasthenia gravis patients binds to a muscle cell line, TE671, but not to human acetylcholine receptor.
por: Blaes, F, et al.
Publicado: (2000)

An audit of the diagnostic usefulness of the NMO-IgG assay for neuromyelitis optica
por: Littleton, E, et al.
Publicado: (2006)

Seroprevalence of Neuromyelitis Optica-IgG of Childhood Compared to Adults
por: J Gordon Millichap
Publicado: (2008-02-01)

Complement activation in patients with neuromyelitis optica
por: Nytrova, P, et al.
Publicado: (2014)

Complement activation in patients with neuromyelitis optica.
por: Nytrova, P, et al.
Publicado: (2014)

Frequency of Aqp4-Ab in patients with neuromyelitis optica (Devic's syndrome) is higher than predicted by NMO-IgG testing
por: Jarius, S, et al.
Publicado: (2007)

Sequential voltage-gated potassium channel and aquaporin-4 antibodies in a patient with seropositive myasthenia gravis, limbic encephalitis and neuromyelitis optica
por: Jacobson, L, et al.
Publicado: (2008)

Detection and characterization of MuSK antibodies in seronegative myasthenia gravis.
por: McConville, J, et al.
Publicado: (2004)

Differentiated pattern of complement system activation between MOG-IgG-associated disease and AQP4-IgG-positive neuromyelitis optica spectrum disorder
por: Eun Bin Cho, et al.
Publicado: (2024-03-01)

Inebilizumab treatment in a patient with co-occurring AQP4-IgG positive neuromyelitis optica spectrum disorder and myasthenia gravis: a case report and literature review
por: Xiaoqian Song, et al.
Publicado: (2025-01-01)

Devic's neuromyelitis optica: Prognostic implications of NMO IgG status in Turkish patients
por: Akman-Demir, G, et al.
Publicado: (2008)

Cerebrospinal fluid/serum gradient of IgG is associated with disability at acute attacks of neuromyelitis optica.
por: Kim, S, et al.
Publicado: (2011)

Intra-cerebral injection of neuromyelitis optica immunoglobulin G and human complement produces neuromyelitis optica lesions in mice.
por: Saadoun, S, et al.
Publicado: (2010)

Revised diagnostic criteria for neuromyelitis optica--incorporation of NMO-IgG status.
por: Jarius, S, et al.
Publicado: (2007)

Clinical and immunological correlates in myasthenia gravis associated with musk antibodies
por: Viegas, S, et al.
Publicado: (2008)

PATHOGENIC MECHANISMS UNDERLYING MYASTHENIA GRAVIS ASSOCIATED WITH MUSK ANTIBODIES
por: Viegas, S, et al.
Publicado: (2009)

Detection of musk antibodies in seronegative myasthenia gravis using human musk as antigen
por: McConville, J, et al.
Publicado: (2002)

Clinical and functional characteristics of seronegative and musk myasthenia gravis
por: Huda, S
Publicado: (2017)

Triple-seronegative myasthenia gravis: clinical and epidemiological characteristics
por: Paula Raquel do Vale Pascoal Rodrigues, et al.
Publicado: (2024-01-01)

Diagnosis and Management of Seronegative Myasthenia Gravis: Lights and Shadows
por: Claudia Vinciguerra, et al.
Publicado: (2023-09-01)

The search for new antigenic targets in myasthenia gravis.
por: Cossins, J, et al.
Publicado: (2012)

Clinical value of cell-based assays in the characterisation of seronegative myasthenia gravis
por: Damato, V, et al.
Publicado: (2022)